Cargando…

Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial

BACKGROUND: Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies between the prescribed and administered doses strongly influence pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration (CVVH) in critically ill...

Descripción completa

Detalles Bibliográficos
Autores principales: Breilh, Dominique, Honore, Patrick M., De Bels, David, Roberts, Jason A., Gordien, Jean Baptiste, Fleureau, Catherine, Dewitte, Antoine, Coquin, Julien, Rozé, Hadrien, Perez, Paul, Attou, Rachid, Redant, Sebastien, Kugener, Luc, Saux, Marie-Claude, Spapen, Herbert D., Ouattara, Alexandre, Joannes-Boyau, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985915/
https://www.ncbi.nlm.nih.gov/pubmed/32010602
http://dx.doi.org/10.2478/jtim-2019-0031
_version_ 1783491873167376384
author Breilh, Dominique
Honore, Patrick M.
De Bels, David
Roberts, Jason A.
Gordien, Jean Baptiste
Fleureau, Catherine
Dewitte, Antoine
Coquin, Julien
Rozé, Hadrien
Perez, Paul
Attou, Rachid
Redant, Sebastien
Kugener, Luc
Saux, Marie-Claude
Spapen, Herbert D.
Ouattara, Alexandre
Joannes-Boyau, Olivier
author_facet Breilh, Dominique
Honore, Patrick M.
De Bels, David
Roberts, Jason A.
Gordien, Jean Baptiste
Fleureau, Catherine
Dewitte, Antoine
Coquin, Julien
Rozé, Hadrien
Perez, Paul
Attou, Rachid
Redant, Sebastien
Kugener, Luc
Saux, Marie-Claude
Spapen, Herbert D.
Ouattara, Alexandre
Joannes-Boyau, Olivier
author_sort Breilh, Dominique
collection PubMed
description BACKGROUND: Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies between the prescribed and administered doses strongly influence pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration (CVVH) in critically ill patients. METHODS: Ancillary data were from the prospective multicenter IVOIRE (hIgh VOlume in Intensive caRE) study. High volume (HV, 70 mL/kg/h) was at random compared with standard volume (SV, 35 mL/kg/h) CVVH in septic shock patients with acute kidney injury (AKI). PK/PD parameters for all antimicrobial agents used in each patient were studied during five days. RESULTS: Antimicrobial treatment met efficacy targets for both percentage of time above the minimal inhibitory concentration and inhibitory quotient. A significant correlation was observed between the ultrafiltration flow and total systemic clearance (Spearman test: P < 0.005) and between CVVH clearance and drug elimination half-life (Spearman test: P < 0.005). All agents were easily filtered. Mean sieving coefficient ranged from 38.7% to 96.7%. Mean elimination half-life of all agents was significantly shorter during HV-CVVH (from 1.29 to 28.54 h) than during SV-CVVH (from 1.51 to 33.85 h) (P < 0.05). CONCLUSIONS: This study confirms that CVVH influences the PK/PD behavior of most antimicrobial agents. Antimicrobial elimination was directly correlated with convection rate. Current antimicrobial dose recommendations will expose patients to underdosing and increase the risk for treatment failure and development of resistance. Dose recommendations are proposed for some major antibiotic and antifungal treatments in patients receiving at least 25 mL/kg/h CVVH.
format Online
Article
Text
id pubmed-6985915
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-69859152020-01-31 Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial Breilh, Dominique Honore, Patrick M. De Bels, David Roberts, Jason A. Gordien, Jean Baptiste Fleureau, Catherine Dewitte, Antoine Coquin, Julien Rozé, Hadrien Perez, Paul Attou, Rachid Redant, Sebastien Kugener, Luc Saux, Marie-Claude Spapen, Herbert D. Ouattara, Alexandre Joannes-Boyau, Olivier J Transl Int Med Original Article BACKGROUND: Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies between the prescribed and administered doses strongly influence pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration (CVVH) in critically ill patients. METHODS: Ancillary data were from the prospective multicenter IVOIRE (hIgh VOlume in Intensive caRE) study. High volume (HV, 70 mL/kg/h) was at random compared with standard volume (SV, 35 mL/kg/h) CVVH in septic shock patients with acute kidney injury (AKI). PK/PD parameters for all antimicrobial agents used in each patient were studied during five days. RESULTS: Antimicrobial treatment met efficacy targets for both percentage of time above the minimal inhibitory concentration and inhibitory quotient. A significant correlation was observed between the ultrafiltration flow and total systemic clearance (Spearman test: P < 0.005) and between CVVH clearance and drug elimination half-life (Spearman test: P < 0.005). All agents were easily filtered. Mean sieving coefficient ranged from 38.7% to 96.7%. Mean elimination half-life of all agents was significantly shorter during HV-CVVH (from 1.29 to 28.54 h) than during SV-CVVH (from 1.51 to 33.85 h) (P < 0.05). CONCLUSIONS: This study confirms that CVVH influences the PK/PD behavior of most antimicrobial agents. Antimicrobial elimination was directly correlated with convection rate. Current antimicrobial dose recommendations will expose patients to underdosing and increase the risk for treatment failure and development of resistance. Dose recommendations are proposed for some major antibiotic and antifungal treatments in patients receiving at least 25 mL/kg/h CVVH. Sciendo 2019-12-31 /pmc/articles/PMC6985915/ /pubmed/32010602 http://dx.doi.org/10.2478/jtim-2019-0031 Text en © 2019 Dominique Breilh et al., published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Original Article
Breilh, Dominique
Honore, Patrick M.
De Bels, David
Roberts, Jason A.
Gordien, Jean Baptiste
Fleureau, Catherine
Dewitte, Antoine
Coquin, Julien
Rozé, Hadrien
Perez, Paul
Attou, Rachid
Redant, Sebastien
Kugener, Luc
Saux, Marie-Claude
Spapen, Herbert D.
Ouattara, Alexandre
Joannes-Boyau, Olivier
Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial
title Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial
title_full Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial
title_fullStr Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial
title_full_unstemmed Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial
title_short Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial
title_sort pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: lessons learned from an ancillary study of the ivoire trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985915/
https://www.ncbi.nlm.nih.gov/pubmed/32010602
http://dx.doi.org/10.2478/jtim-2019-0031
work_keys_str_mv AT breilhdominique pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT honorepatrickm pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT debelsdavid pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT robertsjasona pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT gordienjeanbaptiste pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT fleureaucatherine pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT dewitteantoine pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT coquinjulien pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT rozehadrien pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT perezpaul pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT attourachid pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT redantsebastien pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT kugenerluc pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT sauxmarieclaude pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT spapenherbertd pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT ouattaraalexandre pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT joannesboyauolivier pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial
AT pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial